Home
About
Overview
Sharing Data
ORCID
Help
History (10)
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.
Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer.
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.
The MET axis as a therapeutic target.
See All 10 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
The MET axis as a therapeutic target.
The MET axis as a therapeutic target. Update Cancer Ther. 2009 Apr 01; 3(3):109-118.
View in:
PubMed
authors with profiles
Ravi Salgia